Welcome to our dedicated page for Advanced Biomed SEC filings (Ticker: ADVB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Advanced Biomed Inc. (ADVB) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including registration statements, current reports, and notifications related to its Nasdaq listing. Advanced Biomed is a Nevada-incorporated biotechnology company focused on cancer diagnostics, microfluidic biochips, and precision medicine tools, and its filings offer detailed insight into its capital structure, risk factors, and operational footprint.
Key documents for ADVB include its Form S-1 registration statements, which describe the company’s initial public offering on the Nasdaq Capital Market and an equity line of credit arrangement with a selling stockholder. These filings outline the company’s microfluidic technology platform, devices such as A+Pre, AC-1000, A+CellScan, and A+SCDrop, associated biochips and immunostaining kits, and products like A+LCGuard for early lung cancer screening. They also discuss legal and operational risks tied to subsidiaries in Taiwan, Hong Kong, and Shanghai.
Users can also review Form 8-K current reports, where Advanced Biomed discloses material events such as the launch of the A+PerfusC integrated perfusion 3D cell culture platform and receipt of a Nasdaq notice regarding minimum bid price requirements for continued listing. A Form 12b-25 (NT 10-Q) notification of late filing explains timing for a quarterly report and notes that the company did not anticipate significant changes in results of operations for the referenced period.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points in lengthy documents, helping readers quickly understand financing arrangements, listing status, operational risks, and technology descriptions. Real-time updates from EDGAR, along with structured access to forms such as S-1, 8-K, and 12b-25, make this page a focused resource for analyzing ADVB’s regulatory history and disclosures.
Advanced Biomed Inc. (ADVB) reported a continued operating loss as it advances oncology diagnostics development. For the three months ended September 30, 2025, the company recorded a net loss of $386,901, wider than $265,580 a year earlier, driven mainly by higher research and development spending.
Total operating expenses were $523,914, including $235,992 for research and development and $287,922 for general and administrative costs. Other income, largely foreign exchange gains, added $137,013, partially offsetting expenses. There was no income tax expense.
As of September 30, 2025, Advanced Biomed held cash of $2,656,519 and total assets of $6,242,970, against total liabilities of $3,238,846 and stockholders’ equity of $3,004,124. Operating activities used $610,342 of cash in the quarter. Management discloses substantial doubt about the company’s ability to continue as a going concern but notes support from its March 2025 IPO, which raised $6.56 million in gross proceeds, and an equity line of credit allowing sales of up to $25,000,000 of common stock.
Advanced Biomed Inc. reported an annual 10-K describing a pre-commercial precision oncology business built on a proprietary microfluidic platform and ultra‑sensitive biosensor technology for circulating tumor cell (CTC) capture, identification and single‑cell isolation. The company has completed an Initial Public Offering of 1,640,000 shares at $4.00 per share, generating approximately $5.49M net proceeds. Several products (A+Pre and AC-1000 and corresponding chips) are cleared by the NMPA, while additional instruments and four immunostaining kits are at registration application or review stages.
The filing discloses a consolidated net loss of $3,258,969 for the year and net cash used in operating activities of $5,825,055. Management states these conditions give rise to substantial doubt about going concern, and the company intends to raise additional capital, rely on forthcoming operations, and seek financial support from related parties. The company holds multiple granted patents in China, the U.S., and international PCT filings covering its chips and separation technologies, and reports progress on mass‑production trials with injection molding partners.
Advanced Biomed Inc. filed a current report describing that it issued a press release announcing the launch of its A+PerfusC™ integrated perfusion 3D cell culture platform for precision medicine and drug discovery. The filing mainly serves to furnish this press release as an exhibit for investors and other stakeholders.